Experts Gather for International Breast Cancer Research Conference

Breast cancer specialists from all over the world head to Texas this week for the annual San Antonio Breast Cancer Symposium (SABCS). Now in its 38th year, the conference showcases the latest in breast cancer research. The event, which runs from December 8th through the 12th, is co-sponsored by the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and the Baylor College of Medicine. Get the headlines from the conference from our content partners at CURE.  December 13, 2015Kadcyla Extends Survival in Heavily Pretreated Patients With HER2+ Breast CancerDecember 11, 2015Next-Generation Drug Challenging Imbruvica in CLLDecember 10, 2015Small Study Shows Immunotherapy Effective in Metastatic Breast Cancer SubsetXgeva Generates Survival Benefit in Postmenopausal Women With Breast Cancer
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Breast Cancer Source Type: news

Related Links:

Publication date: Available online 21 February 2019Source: Journal of the Taiwan Institute of Chemical EngineersAuthor(s): Chih-Hsiang Chang, I-Chi Tsai, Chung-Jen Chiang, Yun-Peng ChaoAbstractThe heterogeneous nature of cancers renders the efficacy of the therapeutic treatment diversified. To address this issue, a theranostic approach was proposed by development of a hybrid peptide for simultaneous diagnosis and therapy of cancer cells. Peptide A was composed of the biotinylation site (BS), the HER2/neu-binding motif, and the dockerin domain (Doc). Peptide B was designed with BS and the cohesin domain (Coh). Individually ...
Source: Journal of the Taiwan Institute of Chemical Engineers - Category: Chemistry Source Type: research
ConclusionsAIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative ILC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsMammaPrint and BluePrint test results strongly impacted physicians ’ therapy decisions in luminal EBC with up to three involved lymph nodes. The high adherence to genetically determined risk assessment represents a key prerequisite for achieving a personalized cost-effective approach to disease management of early breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeWe evaluated whether multiplex protein quantification using antibody bar-coding with photocleavable oligonucleotides (NanoString) can be applied to evaluate protein expression in breast cancer FFPE specimens. We also assessed whether diagnostic core-cuts fixed immediately at time of procedures and surgical excision sections from routinely fixed breast cancers are affected by the same fixation related differences noted using immunohistochemistry (IHC).MethodsThe expression of 26 proteins was analysed using NanoString technology in 16 pairs of FFPE breast cancer core-cuts and surgical excisions. The measuremen...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Lambertini M, Viglietti G PMID: 30783509 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
(Johns Hopkins Medicine) In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Condition:   HER2-positive Breast Cancer Intervention:   Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin Sponsor:   Shandong University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Gastric/Gastroesophageal Junction Cancer Intervention:   Drug: KN026 Sponsor:   Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Breast Cancer Intervention:   Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin Sponsor:   Shandong University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Gastric/Gastroesophageal Junction Cancer Intervention:   Drug: KN026 Sponsor:   Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Baylor College of Medicine | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Conferences | Health | HER2 | Immunotherapy | Science | Study | Texas University | Women